Veristat Appoints New Chief Commercial Officer
Veristat, the Science-First Full Service CRO and Consultancy, announced an appointment to its executive leadership team. Rachel Page joins Veristat as Chief Commercial Officer (CCO), succeeding Veristat’s longtime leader Cindy Henderson, who recently transitioned to become Chief Strategy Officer (CSO) to focus on developing and executing Veristat’s customer-driven corporate strategy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240523499154/en/
Rachel Page, Chief Commercial Officer, Veristat (Photo: Business Wire)
With over two decades of experience in global health and science commercialization, Rachel is poised to energize our brand and leverage our deep industry expertise. Her role will be crucial in assisting biopharmaceutical companies as they navigate their most complex clinical and regulatory challenges to speed the delivery of innovative therapies.
“Veristat has a 30-year history of driving innovative approaches that help deliver what are often breakthrough therapies to patients in need,” stated Patrick Flanagan, Chief Executive Officer. “Rachel’s accomplishments and experience empowering people, building commercial organizations, and fostering trusted client relationships demonstrate her ability to successfully lead the execution of our strategic plan. Rachel has received tremendous recognition for her unwavering commitment to client success. I am confident in her ability to leverage Veristat’s deep industry experience on a global scale.”
Rachel’s extensive global network and her successful history in all phases of the pharmaceutical lifecycle will be instrumental in delivering impactful results for our clients.
"I am thrilled to join this dynamic, science-driven team," Rachel commented. "Veristat is exceptional at facilitating the delivery of crucial therapies and transforming client operations. I am honored to collaborate with such a passionate group of executives, colleagues, and clients who are dedicated to accelerating the availability of groundbreaking treatments for patients with complex conditions. I am eager to lead our talented global commercial team and contribute to achieving our clients’ vital objectives."
In her new role, Rachel will oversee Veristat’s commercialization strategy and operations, including business development, proposals, contracts, marketing, and fostering robust client relationships. She will also focus on the growth and development of the commercial team, ensuring continued success in meeting our clients’ needs.
About Veristat
Veristat is the Science-First CRO™ and Consultancy that integrates full service clinical trial execution, regulatory affairs and safety, and strategic advisor services to rapidly advance the development, approval, and commercialization of novel therapies (#NovelTherapies) around the globe. With 30 years of experience solving sponsors' unique and complex clinical, statistical, and regulatory challenges, Veristat Science-First experts deliver timely, quality-driven results with solutions that are tailored to the needs of patients, clinical trial sites, regulators, sponsor teams, and key stakeholders.
Veristat's focus on novel drug development has led to success when handling any unknown that arises, from the simplest to most complex, across numerous therapeutic areas including rare/ultra-rare disease, advanced therapies, oncology, and biologics including cell and gene therapies (#cellandgenetherapy), enabling sponsors to succeed in extending and saving patients’ lives. Sponsors collaborate with Veristat Science-First experts who care— like they do. It is not just business for Veristat, it’s personal.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240523499154/en/
Contact information
Veristat:
Lauren L. Brennan, Vice President of Marketing, Veristat
media@veristat.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
RoslinCT and Ayrmid Pharma Ltd. Announce Their Intent to Enter Into a Strategic Partnership to Manufacture FDA Approved Cell Therapy Omisirge ® (omidubicel-onlv)11.3.2025 12:00:00 CET | Press Release
Ayrmid Pharma Ltd., a cell therapy pioneer working to turn cells into powerful therapeutics and RoslinCT, a world leading cell and gene therapy contract development and manufacturing organization (CDMO), today announced their intent to enter into a strategic partnership for the production of Omisirge, a commercial product for the treatment of hematologic malignancies commercialized in the US by Gamida Cell Inc, a subsidiary of Ayrmid Pharma Ltd. It is the intent of the two companies to enter into an agreement whereby RoslinCT will perform technology transfer and commercial manufacture of Gamida Cell’s Omisirge. The cell-based product is a nicotinamide modified allogeneic hematopoietic progenitor cell therapy that was FDA approved and launched in 2023. It is the intent of the two companies that the technology transfer and commercial manufacturing will take place in RoslinCT's state-of-the-art, purpose-built cell therapy CGMP manufacturing facility in Hopkinton, MA. “As part of our globa
Kinaxis to Unveil the Next Phase of AI Innovation at Kinexions 202511.3.2025 12:00:00 CET | Press Release
Kinaxis® (TSX:KXS), a global leader in end-to-end supply chain orchestration, is set to unveil new artificial intelligence capabilities in its Maestro™ platform at Kinexions North America 2025, the company’s global innovation conference. These AI capabilities are designed to accelerate the value that AI can create in supply chains, helping companies navigate an increasingly volatile global trade environment - whether they are just beginning their AI journey or already leveraging advanced automation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250311610609/en/ The company will introduce AI agents that users can interact with to monitor, predict, and take action in real time — automating key tasks like inventory management and disruption mitigation. In addition, its agentic AI framework will enable companies to easily create their own AI agents on Maestro, making AI-driven supply chain orchestration accessible to businesses
Verne Strikes 10MW Deal with Nebius to Further Expand Europe’s AI Capacity11.3.2025 11:00:00 CET | Press Release
Verne, the leading provider of sustainably powered HPC data centers across the Nordics, has today announced that Nebius, a leading global AI infrastructure provider, will be colocating a cluster of NVIDIA H200 GPUs at Verne’s data center campus in Iceland. This collaboration marks the largest single implementation in Verne Iceland’s history, with Nebius deploying a 10MW cluster. This installation is part of Nebius’ ambitious build-out of AI infrastructure across the US and Europe, supporting its mission to provide scalable, energy-efficient solutions for intensive AI workloads. As one of Europe’s leading providers of GPU capacity, Nebius selected Verne for its proven expertise, renewable energy-driven operations, and ability to meet precise technical and geographical requirements. Verne’s Icelandic facility, uniquely located on a former NATO base and powered entirely by Iceland’s 100% renewable hydroelectric and geothermal energy resources, aligns perfectly with Nebius’ approach to ado
Allegro DVT Launches its First AI-Based Neural Video Processing IP11.3.2025 10:35:00 CET | Press Release
Allegro DVT, a leader in video processing semiconductor solutions, is excited to announce the launch of its latest innovation, its first AI-based Neural Video Processing NVP300 IP. This groundbreaking product marks Allegro DVT’s commitment to embrace the AI revolution and push video quality to the next level, leveraging the advanced features and benefits of AI based video processing technologies. The new NVP300 semiconductor IP features an optimized hardware implementation to deliver real-time AI processing of 4K video within best-in-class silicon area and power budget suitable for embedded products. "We are thrilled to introduce our first AI-based Neural Video Processing IP to the market," said Nouar Hamze, CEO at Allegro DVT. "The NVP300 represents a significant advancement in video processing technology offering stunning subjective video quality improvements. It will greatly benefit our customers to power their next generation video compression solutions." The launch of the AI-based
Interactive Brokers Expands Global Reach with Ljubljana Stock Exchange Access11.3.2025 10:00:00 CET | Press Release
Interactive Brokers (Nasdaq: IBKR), an automated global electronic broker, announced today that it has expanded its market offerings by adding access to the Ljubljana Stock Exchange. With this expansion, clients can trade Slovenian equities alongside products from over 160 other global exchanges, including stocks, options, futures, currencies, bonds, funds, and more, from a single unified platform. Enhancing Market Access for Global Investors Interactive Brokers provides access to over 160 markets across the Americas, Europe, and Asia, and adding the Ljubljana Stock Exchange further broadens the investment opportunities for our active traders and institutional investors. Clients can now include Slovenian stocks as part of their portfolio diversification strategies, complementing their European and global investments. "Interactive Brokers continues to expand its market coverage to meet the needs of global investors," said Milan Galik, Chief Executive Officer of Interactive Brokers. "Add
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom